Besides CAR-T direct tumor killing activity, secreted PD-1 nanobodies may provide additional clinical benefit by invigorating CAR-T from PD-L1 inhibition, activating TILs and relieving local immunosuppression.Zhuqing LiuYong XiaLinlin LiYan Sun...
Here, we have developed CAR-T cells that exploit the binding capacity of mesothelin to MUC16. We find that MSLN-CAR T cells effectively eliminate ovarian cancer tumor cells and stem-like cells in vitro, and this cytotoxic function is dependent on high expression levels of MUC16 on the tumor...
expressed by pericardial tissue. In a separate, ongoing clinical trial (NCT02414269), patients are being treated with intrapleural delivery of mesothelin-targeting CD28ζ CAR T cells followed by maintenance anti PD-1antibody therapy. This combinatorial approach has demonstrated superior efficacy as ...
The phase I clinical trial showed that a CAR T-cell therapy targeting the mesothelin has significant antitumor activity and no obvious toxicity in patients with the malignant pleural disease from mesothelioma. ADCs as a new therapy strategy has been developed for the treatment of the mesothelin-...
Since the approval of chimeric antigen receptor (CAR) T cell therapy targeting CD19 by the FDA, CAR-T cell therapy has received increasing attention as a new method for targeting tumors. Although CAR-T cell therapy has a good effect against hematological malignancies, it has been less ...
Mesothelin (MSLN) is an attractive antigen for chimeric antigen receptor (CAR) T therapy and the epitope selection within MSLN is essential. In this study, we constructed two types of CARs targeting either region I of MSLN (meso1 CAR, also known as a membrane-distal region) or region III ...
CAR-T cell therapy targeting CD19 has achieved remarkable success in the treatment of B cell malignancies, while various solid malignancies are still refractory for lack of suitable target. In recent years, a large number of studies have sought to find s
T cell receptor fusion constructs (TRuC) consist of an antibody-based single chain variable fragment (scFv) fused to a T cell receptor chain (TCR) and allow recognition of cancer cells in an HLA-independent manner. Unlike chimeric antigen receptors (CAR), TRuC are integrated into the TCR comp...
Numerous clinical trials for MSLN-targeting methods gave promising results, as targeting MSLN with antibodies, antibody derivatives, antibody–drug conjugates, immunotoxin and CAR-T cells for therapy (Table 2). To give some examples, in a phase I trial of SS1P, an anti- MSLN immunotoxin, ...
Preclinical results and early clinical studies employing Anetumab ravtansine were very promising [14, 16]. In a recent phase II trial the therapeutic potential of Anetumab ravtansine was explored as second line therapy in 248 mes- othelioma patients who were no longer responsive to the ...